FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA ...
One of the most problematic issues in investigations of the female sexual response is the limited availability of a reliable physiological measure of genital arousal. In men, penile tumescence and ...
SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel ...
Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder (FSAD) ...
Dare Bioscience (DARE) announced plans for a Phase 3 study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female ...
Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, with self-reported arousal difficulties reported in up to 26% of American women. Various oral therapies for ...
FSAD, which affects an estimated 10 million women in the U.S., is characterized by a persistent inability to maintain sufficient genital arousal. Currently, no FDA-approved pharmacological treatments ...
SAN DIEGO - Daré Bioscience, Inc. (NASDAQ: DARE) has announced that its topical Sildenafil Cream, 3.6%, intended for female sexual arousal disorder (FSAD), demonstrated safety and tolerability in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback